BTBD2

Summary

BTBD2 (BTB domain containing 2, HGNC:15504) is a protein-coding gene on chromosome 19p13.3, encoding BTB/POZ domain-containing protein 2 (Q9BX70).

The C-terminus of the protein encoded by this gene binds topoisomerase I. The N-terminus contains a proline-rich region and a BTB/POZ domain (broad-complex, Tramtrack and bric a brac/Pox virus and Zinc finger), both of which are typically involved in protein-protein interactions. Subcellularly, the protein localizes to cytoplasmic bodies.

Source: NCBI Gene 55643 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 114 total
• MANE Select transcript: NM_017797

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15504
Approved symbol	BTBD2
Name	BTB domain containing 2
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000133243
Ensembl biotype	protein_coding
OMIM	608531
Entrez	55643

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 7 protein_coding, 4 retained_intron, 1 nonsense_mediated_decay

ENST00000255608, ENST00000587225, ENST00000587742, ENST00000587825, ENST00000588395, ENST00000589200, ENST00000589685, ENST00000590646, ENST00000592082, ENST00000592895, ENST00000611545, ENST00000936983

RefSeq mRNA: 1 — MANE Select: NM_017797 NM_017797

CCDS: CCDS12078

Canonical transcript exons

ENST00000255608 — 9 exons

Exon	Start	End
ENSE00001055897	2015297	2015714
ENSE00003468647	1990004	1990201
ENSE00003481733	1986830	1986976
ENSE00003508526	1990717	1990822
ENSE00003547077	1985448	1986649
ENSE00003562305	1993020	1993176
ENSE00003566477	1987500	1987692
ENSE00003636242	1987166	1987253
ENSE00003637208	1997344	1997463

Expression profiles

Bgee: expression breadth ubiquitous, 232 present calls, max score 98.03.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.5797 / max 126.1598, expressed in 1788 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178098	20.8519	1786
178097	0.5742	371
178099	0.1536	88

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right frontal lobe	UBERON:0002810	98.03	gold quality
right hemisphere of cerebellum	UBERON:0014890	98.02	gold quality
cerebellar hemisphere	UBERON:0002245	97.63	gold quality
cerebellar cortex	UBERON:0002129	97.53	gold quality
cingulate cortex	UBERON:0003027	97.52	gold quality
anterior cingulate cortex	UBERON:0009835	97.52	gold quality
stromal cell of endometrium	CL:0002255	97.13	gold quality
right uterine tube	UBERON:0001302	96.98	gold quality
amygdala	UBERON:0001876	96.95	gold quality
lower esophagus mucosa	UBERON:0035834	96.68	gold quality
right ovary	UBERON:0002118	96.56	gold quality
ventricular zone	UBERON:0003053	96.46	gold quality
cortical plate	UBERON:0005343	96.44	gold quality
apex of heart	UBERON:0002098	96.39	gold quality
left ovary	UBERON:0002119	96.33	gold quality
cerebellum	UBERON:0002037	96.17	gold quality
ganglionic eminence	UBERON:0004023	96.10	gold quality
prefrontal cortex	UBERON:0000451	95.64	gold quality
right lobe of thyroid gland	UBERON:0001119	95.53	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.49	gold quality
nucleus accumbens	UBERON:0001882	95.46	gold quality
endocervix	UBERON:0000458	95.32	gold quality
body of uterus	UBERON:0009853	95.31	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.29	gold quality
granulocyte	CL:0000094	95.22	gold quality
left uterine tube	UBERON:0001303	95.22	gold quality
adenohypophysis	UBERON:0002196	95.19	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.09	gold quality
ectocervix	UBERON:0012249	95.07	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.06	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.64

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

24 targeting BTBD2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-128-2-5P	99.33	60.83	311
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-143-5P	98.98	68.87	946
HSA-MIR-6829-5P	98.86	65.12	1480
HSA-MIR-873-5P	98.84	66.90	1348
HSA-MIR-6838-3P	98.40	65.88	559
HSA-MIR-637	97.91	64.05	1517
HSA-MIR-296-5P	97.61	64.02	851
HSA-MIR-122-5P	97.23	64.92	1024
HSA-MIR-6815-5P	96.05	65.55	662
HSA-MIR-6865-5P	96.05	65.58	675
HSA-MIR-3622B-5P	94.62	64.58	835
HSA-MIR-4743-5P	88.08	64.31	91
HSA-MIR-1247-5P	85.92	61.07	65

Literature-anchored findings (GeneRIF, showing 3)

• subcellular colocalization of BTBD1 and BTBD2 to cytoplasmic bodies; TRIM5delta colocalized with BTBD1/2 and appeared to serve as a scaffold for the assembly of endogenous BTBD1/2 proteins (PMID:12878161)
• Polymorphisms in the LIG4, BTBD2, HMGA2, and RTEL1 genes, which are involved in the double-strand break repair pathway, are associated with glioblastoma multiforme survival. (PMID:20368557)
• Interaction of BTBD1 and BTBD2 with TOP1 requires TOP1 residues 236 and 237, the same residues required to enhance the infectivity of progeny virions when TOP1 is expressed in African Green Monkey producer cells. (PMID:21092135)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	btbd2a	ENSDARG00000042091
danio_rerio	btbd2b	ENSDARG00000104653
mus_musculus	Btbd2	ENSMUSG00000003344
rattus_norvegicus	Btbd2	ENSRNOG00000018788
drosophila_melanogaster	BTBD9	FBGN0030228
drosophila_melanogaster	CG17068	FBGN0031098
drosophila_melanogaster	lute	FBGN0262871
caenorhabditis_elegans		WBGENE00015463

Paralogs (11): BTBD1 (ENSG00000064726), ABTB1 (ENSG00000114626), SPOP (ENSG00000121067), KBTBD4 (ENSG00000123444), BTBD3 (ENSG00000132640), SPOPL (ENSG00000144228), ABTB3 (ENSG00000151136), ABTB2 (ENSG00000166016), KLHL11 (ENSG00000178502), BTBD9 (ENSG00000183826), BTBD6 (ENSG00000184887)

Protein

Protein identifiers

BTB/POZ domain-containing protein 2 — Q9BX70 (reviewed: Q9BX70)

All UniProt accessions (7): A0A087WUX2, A0A087WXN3, A0A087WY57, A0A087X147, Q9BX70, K7EMW9, K7ENV9

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Interacts with topoisomerase 1 and with TRIM5 isoform Delta.

Subcellular location. Cytoplasm.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BX70-1	1	yes
Q9BX70-2	2

RefSeq proteins (1): NP_060267* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR011705	BACK	Domain
IPR012983	PHR	Domain
IPR038648	PHR_sf	Homologous_superfamily

Pfam: PF00651, PF07707, PF08005

UniProt features (25 total): strand 14, compositionally biased region 4, turn 2, chain 1, domain 1, region of interest 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3NO8	X-RAY DIFFRACTION	2.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BX70-F1	84.82	0.68

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 96 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GSE45365_NK_CELL_VS_CD11B_DC_UP, AAGCCAT_MIR135A_MIR135B, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, GOBP_NEUROGENESIS, BROWNE_HCMV_INFECTION_48HR_DN, RICKMAN_METASTASIS_DN, CAATGCA_MIR33, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, SENESE_HDAC3_TARGETS_DN, GOCC_RIBONUCLEOPROTEIN_GRANULE, chr19p13, MORF_ACTG1, VERHAAK_GLIOBLASTOMA_CLASSICAL, GOCC_P_BODY

GO Biological Process (1): neurogenesis (GO:0022008)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): P-body (GO:0000932), cytosol (GO:0005829), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
nervous system development	1
cell differentiation	1
binding	1
cytoplasmic ribonucleoprotein granule	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

646 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BTBD2	TRIM5	Q9C035	942
BTBD2	TOP1	P11387	811
BTBD2	UBE2D2	P51669	613
BTBD2	CUL3	Q13618	598
BTBD2	RBX1	P62877	543
BTBD2	WDSUB1	Q8N9V3	539
BTBD2	HESX1	Q9UBX0	518
BTBD2	SIAH1	Q8IUQ4	506
BTBD2	TRIM34	Q9BYJ4	494
BTBD2	TRIM6	Q9C030	492
BTBD2	LONP2	Q86WA8	489
BTBD2	TOB1	P50616	482
BTBD2	LMBRD2	Q68DH5	466
BTBD2	TOPORS	Q9NS56	462
BTBD2	CHD3	Q12873	439

IntAct

127 interactions, top by confidence:

A	B	Type	Score
CUL3	KLHL12	psi-mi:“MI:0914”(association)	0.920
COPS5	COPS2	psi-mi:“MI:0914”(association)	0.910
COPS2	GPS1	psi-mi:“MI:0914”(association)	0.860
COPS8	COPS2	psi-mi:“MI:0914”(association)	0.850
COPS5	CUL4A	psi-mi:“MI:0914”(association)	0.840
CUL3	BTBD2	psi-mi:“MI:0915”(physical association)	0.800
COPS6	RHOBTB1	psi-mi:“MI:0914”(association)	0.730
BTBD1	BTBD2	psi-mi:“MI:0403”(colocalization)	0.620
BTBD2	BTBD1	psi-mi:“MI:0403”(colocalization)	0.620
PSMD5	BTBD2	psi-mi:“MI:0915”(physical association)	0.560
MLH1	BTBD2	psi-mi:“MI:0915”(physical association)	0.560
BTBD2	OSGIN1	psi-mi:“MI:0915”(physical association)	0.560
CCNC	BTBD2	psi-mi:“MI:0915”(physical association)	0.560
BTBD2	NGB	psi-mi:“MI:0915”(physical association)	0.560
CINP	BTBD2	psi-mi:“MI:0915”(physical association)	0.560
NTAQ1	BTBD2	psi-mi:“MI:0915”(physical association)	0.560
COPS5	KLHL18	psi-mi:“MI:0914”(association)	0.530
CUL3	RHOBTB1	psi-mi:“MI:0914”(association)	0.530
BTBD1	TRAPPC10	psi-mi:“MI:0914”(association)	0.530
COPS3	HBB	psi-mi:“MI:0914”(association)	0.530

BioGRID (102): BTBD2 (Affinity Capture-Western), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS), BTBD2 (Affinity Capture-MS)

ESM2 similar proteins: A0A072VIM5, A2AQW0, B5X561, F4JSE7, O04615, O35099, O81916, O82343, O94955, P58544, Q0IY07, Q0JC27, Q10MI4, Q2HW56, Q53NI2, Q5ZJ87, Q66J91, Q6E7H0, Q6PNC0, Q6ZN16, Q7ZX59, Q80WG7, Q84UI6, Q8CFE5, Q8LPQ5, Q8NEA9, Q8S8F2, Q8VYP9, Q8VZF6, Q8W032, Q8W519, Q94BM7, Q99683, Q9BX70, Q9CAJ9, Q9CTN4, Q9FLR0, Q9FNP1, Q9FPW6, Q9FYF9

Diamond homologs: A0A2R8Q1W5, A4IFG2, A9JRD8, B7U179, F1RD40, F7ASZ0, G3X9X1, M3XQV7, O75592, P57790, P58544, P58545, Q0V9W6, Q14145, Q17551, Q2LE78, Q5R774, Q5TZE1, Q684M4, Q7TPH6, Q8BHI4, Q8IY47, Q8K2J9, Q96KE9, Q96Q07, Q9BX70, Q9H0C5, Q9W2S3, Q9Y2F9, Q9Z2X8, A6NED2, D3ZGQ5, O95199, O95714, P0C5Y8, P18754, P23800, P25171, P25183, Q15034

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 86 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
DNA Damage Recognition in GG-NER	10	52.9×	9e-13
Formation of TC-NER Pre-Incision Complex	10	39.2×	1e-11
Cargo recognition for clathrin-mediated endocytosis	9	17.5×	2e-07
Neddylation	12	10.5×	2e-07

GO biological processes:

GO term	Partners	Fold	FDR
regulation of protein neddylation	8	97.3×	2e-12
protein neddylation	7	63.8×	2e-09

Disease & clinical

Clinical variants and AI predictions

ClinVar

114 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	89
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1282 predictions. Top by Δscore:

Variant	Effect	Δscore
19:1986645:GGGCC:G	acceptor_gain	1.0000
19:1986646:GGCC:G	acceptor_gain	1.0000
19:1986647:GCC:G	acceptor_gain	1.0000
19:1986648:CC:C	acceptor_gain	1.0000
19:1986648:CCC:C	acceptor_gain	1.0000
19:1986649:CCTG:C	acceptor_gain	1.0000
19:1986650:C:CC	acceptor_gain	1.0000
19:1986650:CTGTA:C	acceptor_loss	1.0000
19:1986651:T:C	acceptor_loss	1.0000
19:1986826:GCAC:G	donor_loss	1.0000
19:1986827:CACC:C	donor_loss	1.0000
19:1986972:ATAAT:A	acceptor_gain	1.0000
19:1986973:TAAT:T	acceptor_gain	1.0000
19:1986974:AAT:A	acceptor_gain	1.0000
19:1986974:AATC:A	acceptor_loss	1.0000
19:1986975:AT:A	acceptor_gain	1.0000
19:1986976:TC:T	acceptor_loss	1.0000
19:1986977:C:CA	acceptor_loss	1.0000
19:1986977:C:CC	acceptor_gain	1.0000
19:1986978:T:G	acceptor_loss	1.0000
19:1987162:GTAC:G	donor_loss	1.0000
19:1987163:TA:T	donor_loss	1.0000
19:1987164:A:C	donor_loss	1.0000
19:1987165:C:A	donor_loss	1.0000
19:1987252:ACCT:A	acceptor_loss	1.0000
19:1987254:C:A	acceptor_loss	1.0000
19:1987499:C:CA	donor_loss	1.0000
19:1987692:CCT:C	acceptor_loss	1.0000
19:1987693:C:CC	acceptor_gain	1.0000
19:1987693:C:CG	acceptor_loss	1.0000

AlphaMissense

3413 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:1986510:G:C	P519R	1.000
19:1986510:G:T	P519H	1.000
19:1986513:A:C	I518S	1.000
19:1986513:A:G	I518T	1.000
19:1986513:A:T	I518N	1.000
19:1986515:C:A	Q517H	1.000
19:1986515:C:G	Q517H	1.000
19:1986516:T:C	Q517R	1.000
19:1986519:C:A	G516V	1.000
19:1986519:C:G	G516A	1.000
19:1986519:C:T	G516D	1.000
19:1986520:C:A	G516C	1.000
19:1986520:C:G	G516R	1.000
19:1986520:C:T	G516S	1.000
19:1986521:G:C	D515E	1.000
19:1986521:G:T	D515E	1.000
19:1986522:T:A	D515V	1.000
19:1986522:T:G	D515A	1.000
19:1986523:C:A	D515Y	1.000
19:1986523:C:G	D515H	1.000
19:1986525:T:A	E514V	1.000
19:1986526:C:T	E514K	1.000
19:1986531:G:A	S512F	1.000
19:1986531:G:T	S512Y	1.000
19:1986532:A:G	S512P	1.000
19:1986534:G:A	T511I	1.000
19:1986534:G:C	T511R	1.000
19:1986534:G:T	T511K	1.000
19:1986535:T:C	T511A	1.000
19:1986537:C:A	G510V	1.000

dbSNP variants (sampled 300 via entrez): RS1000225194 (19:2009316 A>G), RS1000316997 (19:1985037 C>T), RS1000334046 (19:2004684 G>A), RS1000495959 (19:2009160 A>G), RS1000498033 (19:1996622 G>A), RS1000615184 (19:2003854 A>T), RS1000654965 (19:1996910 C>T), RS1000658560 (19:1986428 A>C,T), RS1000667777 (19:2012485 G>A), RS1000767633 (19:2000155 G>A), RS1000935831 (19:2012283 G>A), RS1001047967 (19:2004063 T>TCAATG), RS1001100328 (19:2007664 A>C), RS1001146848 (19:2012662 C>T), RS1001155417 (19:2016228 A>C)

Disease associations

OMIM: gene MIM:608531 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST004603_189	Platelet count	8.000000e-09
GCST007396_2	Mitochondrial DNA copy number (white blood cells)	5.000000e-08
GCST90002400_257	Plateletcrit	1.000000e-09
GCST90002401_569	Platelet distribution width	6.000000e-18
GCST90002402_607	Platelet count	4.000000e-15

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0006312	mitochondrial DNA measurement
EFO:0007985	platelet crit
EFO:0007984	platelet component distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, decreases methylation	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
aristolochic acid I	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
cupric chloride	decreases expression	1
nickel sulfate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
ICG 001	increases expression	1
abrine	decreases expression	1
bisphenol AF	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Arsenic Trioxide	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Carcinogens	decreases expression	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Quercetin	increases expression	1
Smoke	decreases expression	1
Dronabinol	increases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
Zinc	affects expression	1
Cyclosporine	decreases methylation	1
Okadaic Acid	decreases expression	1
tert-Butylhydroperoxide	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery